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Extrapolation of clinical data from other indications is an important concept in the
development of biosimilars. This process depends on strict comparability exercises to establish
similarity to the reference medicinal product. However, the extrapolation paradigm has
prompted a fierce scientific debate. CT-P13 (Remsima, Inflectra), an infliximab biosimilar, is
a TNF antagonist used to treat immune-mediated inflammatory diseases. On the basis of
totality of similarity data, the EMA approved CT-P13 for all indications held by its reference
medicinal product (Remicade) including inflammatory bowel disease. This article reviews the
mechanisms of action of TNF antagonists in immune-mediated inflammatory diseases and
illustrates the comparable profiles of CT-P13 and reference medicinal product on which the
extrapolation of indications including inflammatory bowel disease is based.
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The extrapolation of safety and efficacy data
from one clinical indication to another is a
scientific principle that may be utilized in cer-
tain situations during biologic drug develop-
ment. For a novel or ‘originator’ biologic, this
concept may be applied when a major change
in the manufacturing process is thought to
have the potential to impact the clinical profile
of the drug [1]. In most instances, where a
change in the manufacturing process for an
originator biologic has occurred, no clinical
studies at all are required. However, when
major changes that may have a clinical impact
take place – and after it has been demonstrated
that the nonclinical characteristics of the drug
are sufficiently similar before and after the pro-
cess change – it is usual for new clinical data to
be collected in one indication and then
‘extrapolated’ to other indications held by the
drug [1]. This extrapolation concept is, how-
ever, more commonly utilized during develop-
ment of a similar biologic medicinal product
(or ‘biosimilar’). In this case, if similarity
between a biosimilar and its originator drug (or
‘reference medicinal product’ [RMP]) is dem-
onstrated in one indication, approval of the
biosimilar in all indications held by the RMP
may be granted. Such approval, however,
requires the demonstration of comparability in
quality, nonclinical and clinical data, as well as
an evidence-based justification for extrapolation
as outlined in biosimilar guidelines issued by
the EMA [2]. This justification should include
evidence that the mechanism(s) of action of the
drug in question is the same in all indications
involved in the extrapolation process. Despite
the regulatory requirement to justify extrapola-
tion, concerns have been expressed regarding
the scientific validity of this approach, in par-
ticular whether it is appropriate to use a biosi-
milar in an indication in which the efficacy and
safety of the biosimilar have not been formally
evaluated [3–5].
CT-P13 (Remsima, Inflectra) is a biosi-
milar of infliximab, a human–murine chimeric
monoclonal antibody (mAb) against TNF that




























is used in the treatment of various immune-mediated inflamma-
tory diseases (IMIDs) [6]. CT-P13 was approved by the EMA in
September 2013 for all indications held by the infliximab RMP
(Remicade), namely rheumatoid arthritis (RA), ankylosing
spondylitis (AS), psoriatic arthritis (PsA), psoriasis (PsO), adult
and pediatric Crohn’s Disease (CD) and adult and pediatric
ulcerative colitis (UC) [7,8]. European approval for these indica-
tions was based on the acknowledgment that the main mecha-
nism of action of infliximab in the different indications was the
same and on data from a comprehensive nonclinical study pro-
gram, which showed that all major physicochemical characteris-
tics and biologic activities of CT-P13 and RMP were
comparable [8,9] plus two clinical trials in which RA or AS
patients were treated with the biosimilar or the RMP [10,11]. Out-
side of Europe, Health Canada granted approval of CT-P13 for
the treatment of RA, AS, PsA or PsO but not for inflammatory
bowel disease (IBD; i.e., CD and UC) [12]. Such discrepancies in
regulatory approaches add to the confusion surrounding the
scientific validity of extrapolation in biosimilar development.
In this article, we use the example of CT-P13 as a means to
explain the scientific and regulatory principles that underlie the
rationale for extrapolation. We begin by considering the physi-
cochemical characterization of two infliximab molecules and
the role of TNF and TNF antagonists in the pathogenesis and
treatment of IMIDs, as a means to explain the rationale for
extrapolation of the clinical data for CT-P13 to IBD
indications.
Physicochemical characterization of CT-P13 & RMP
The physicochemical characteristics of CT-P13 and infliximab
RMP have been compared using the current state-of-art tech-
nology [9]. Thorough comparability analysis showed that CT-
P13 possesses highly similar properties in terms of primary/
higher order structures and purity/impurity. Regarding charge
isoforms, there are noticeable differences in the relative propor-
tion of basic variants in CT-P13 and RMP. However, the
amount of basic variants derived from C-terminal lysine was
shown to have no effect on biological potency due to rapid
clipping by carboxypeptidase B in vivo [9]. There are also
numerical differences in fucosylation between CT-P13 and
infliximab RMP. Consequently, and as discussed in detail
below, CT-P13 has a lower binding affinity for FcgRIIIa than
for RMP, with lower levels of antibody-dependent cellular cyto-
toxicity (ADCC) being observed with CT-P13 in an in vitro
model using natural killer (NK) cells as effector cells and trans-
membrane TNF (tmTNF)-expressing Jurkat cells as target cells.
However, as demonstrated in other models that are more repre-
sentative of pathophysiological conditions (see below), differen-
ces in fucosylation and FcgRIIIa binding between CT-P13 and
infliximab RMP are not likely to be clinically relevant [8].
TNF & TNF antagonists in the pathogenesis & treatment
of IMIDs: a brief overview
Despite their varying clinical presentation, IMIDs such as
RA, AS, PsO, PsA and IBD share similar mechanisms of
pathogenesis, most notable of which is the overexpression
of TNF [13]. TNF is a proinflammatory cytokine with a
well-characterized physiological profile [14]. It is produced by
various immune and nonimmune cells including macrophages,
T lymphocytes, neurons and keratinocytes. The stimulation of
TNF-producing cells leads to the expression of tmTNF, which
can be cleaved, releasing soluble TNF (sTNF). tmTNF and
sTNF bind to TNF receptors (TNFRs) on the cell surface of
TNF-responsive cells, initiating various intracellular signaling
pathways, including those involved in the initiation of apopto-
sis and the regulation of genes involved in inflammation [14].
Evidence for the involvement of TNF in IBD also includes
the greatly increased number of TNF-producing cells in the
lamina propria of the bowel in IBD patients [15,16] and
increased TNF concentrations in the stools of children with
active IBD [17]. The central role of TNF overexpression in the
pathogenesis of IMIDs is also reflected by the efficacy of vari-
ous biologic drugs that inhibit its function. TNF antagonists
approved for use in different IMID indications include inflixi-
mab, etanercept, adalimumab, certolizumab and golimumab [18].
All are TNF-specific mAbs, or fragments thereof, with the
exception of etanercept, which is a fusion protein between the
extracellular portions of TNFR2 and the Fc portion of human
IgG1 [14]. Although inhibition of TNF is believed to be the
common denominator underlying the therapeutic activity of
these agents, different TNF-driven mechanisms of disease have
been identified (see next section). While some of these mecha-
nisms occur in numerous IMIDs, others may be unique to a
single indication. Structural differences between TNF antago-
nists affect their ligand-binding characteristics, which in turn
lead to some differences in the TNF mechanisms of action
(MOAs) that are targeted by these agents [14]. In the following
section, we consider the TNF biochemical pathways that may
be important in IBD and review the studies that have com-
pared the effects of CT-P13 and the infliximab RMP on these
TNF MOAs.
Targeting the possible MOAs of TNF in IBD: how do
CT-P13 & RMP compare?
Binding & neutralization of sTNF & tmTNF
The primary mechanism via which infliximab is thought to
exert its therapeutic effect in IBD and other IMIDs is by bind-
ing to sTNF and tmTNF and thereby preventing TNFR bind-
ing and activation (FIGURE 1). Such neutralization of TNF activity
leads to suppression of numerous proinflammatory processes
including induction of other proinflammatory cytokines (e.g.,
interleukin [IL]-1 and IL-6) [14]; enhancement of leukocyte
migration [19]; neutrophil and eosinophil activation [19,20];
induction of acute phase reactants and other liver proteins [14];
and induction of apoptosis in tissue cells [21]. This MOA is
common to all TNF antagonists and is relevant to all indica-
tions for which infliximab is licensed in Europe and elsewhere.
The TNF binding and neutralization activities of CT-P13 and
infliximab RMP have been compared in vitro using ELISA and
cell-based assays and shown to be equivalent [9].
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Induction of reverse signaling
Signaling by tmTNF occurs not only by conventional
ligand–receptor interactions but also via a process called reverse
signaling. This process involves tmTNF acting as a receptor, in
contrast to its usual role as a ligand. In this mode, the tmTNF
sends signals back into tmTNF-expressing cells, which activate
signaling pathways culminating in a number of downstream
effects including apoptosis and cytokine suppression [14,22,23].
The existence of a role for reverse signaling in mediating a
therapeutic response in IBD is supported by two related facts
that: whereas infliximab and other mAb TNF antagonists are
capable of inducing reverse signaling, etanercept is not; and
whereas these mAbs are effective in IBD indications, etanercept
had no such activity at the doses tested (perhaps suggesting
that higher doses or more frequent dosing may be required in
IBD) [24–26].
The extent of blockade of proinflammatory cytokine produc-
tion by reverse signaling through tmTNF has been shown to
be comparable for CT-P13 and RMP using peripheral blood
mononuclear cells from healthy donors or patients with CD [8].
Furthermore, the reverse signaling-driven apoptotic effects of
these two drugs have also been shown to be comparable in
Jurkat cells stably transfected with tmTNF [8,9] In the latter
assay, the average (range) activity of CT-P13 and RMP
Figure 1. Diagrammatic representation of the mechanisms of action of infliximab. Binding of infliximab blocks the interaction of
sTNF with TNFR1 and TNFR2 and prevents release of proinflammatory cytokines and apoptosis of the TNFR-bearing cell. This mechanism
is common to all TNF antagonists and relevant to all indications for infliximab. Binding of infliximab to tmTNF blocks the forward signal-
ing mechanisms but activates the reverse signaling pathways. Binding to tmTNF is considered particularly important in IBD because effects
mediated through reverse signaling into tmTNF-bearing cells may include cytokine suppression, induction of apoptosis and induction of
regulatory macrophages. Evidence from a range of TNF antagonists indicates that suppression of bacterially stimulated cytokine induction
is also key for the therapeutic effect in IBD. The role for other mechanisms such as cytotoxicity is speculative and a matter of
debate [14,19,31,32,34,62].
ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity; IBD: Inflammatory bowel disease;
sTNF: Soluble tumor necrosis factor; tmTNF: Transmembrane tumor necrosis factor; TNFR: Tumor necrosis factor receptor.




























standardized as a percentage value was 101% (91–105) and
101% (92–110), respectively (p < 0.0001 for equivalence) [9].
Regulatory macrophage induction & wound healing
Macrophages are involved in all phases of wound healing,
including inflammation, the creation of granulation tissue, and
matrix deposition [27]. Both proinflammatory ‘M1’ macro-
phages and anti-inflammatory or regulatory ‘M2’ macrophages
exist and their relative distribution is thought to be important
in the etiology of IBD. The lamina propria macrophages of
patients with IBD are predominantly M1 [28,29]. It is known
that the production of M1 macrophages is stimulated by expo-
sure to TNF [30] and can therefore be inhibited by infliximab.
Macrophage populations can be affected by TNF antagonists,
which may play a role in the therapeutic response elicited in
patients with IBD. Studies by Vos et al. have shown that inflix-
imab and adalimumab, but not certolizumab, are able to
decrease the proliferation capacity of activated T cells in the
environment of a mixed lymphocyte reaction but not in assays
using isolated T-cell populations [31]. The authors suggested
that in order for infliximab to inhibit T-cell proliferation
in vitro, the antibody needs to bind to tmTNF on activated
T cells and to possess an Fc region that can interact with the
Fc receptor on antigen-presenting cells, such as macrophages
that are present in a mixed lymphocyte reaction environment.
Upon binding, the production of a regulatory macrophage sub-
set occurs which exhibits immunosuppressive capacities, includ-
ing the production of anti-inflammatory cytokines and the
inhibition of T-cell proliferation. Further studies in patients
with IBD demonstrated that the numbers of regulatory macro-
phages increased in patients with IBD who responded to inflix-
imab treatment with evidence of mucosal healing, but not in
nonresponders [32]. This induction of regulatory macrophages
and subsequent inhibition of T-cell proliferation appears to be
an important MOA of infliximab in IBD.
The comparability of CT-P13 and infliximab RMP was
investigated in mixed lymphocyte reaction assays using periph-
eral blood mononuclear cells from healthy and CD donors. To
remove any confounding effect of FcgRIIIa receptor polymor-
phisms on the binding, genotype-matched peripheral blood
mononuclear cells were used. No differences were detected
between CT-P13 and RMP in the proportion of regulatory
macrophages induced or in inhibition of T-cell proliferation [8].
Cytotoxicity
Monoclonal antibodies such as infliximab may, in theory,
induce cytotoxicity against tmTNF-bearing cells via
complement-dependent cytotoxicity (CDC) and/or ADCC.
Although there is no evidence for a role of CDC in the effects
of infliximab in vivo, the comparative ability of CT-P13
and the infliximab RMP to induce CDC has been investigated
in Jurkat cells overexpressing tmTNF. No differences in
the ability of CT-P13 and RMP to induce lysis of these cells
via CDC were detected; average (range) activity of CT-P13
and RMP standardized as a percentage value was 102%
(91–116) and 93% (84–115), respectively (p = 0.0011 for
equivalence) [8,9].
ADCC is the immune defense mechanism whereby immune
effector cells such as macrophages or NK cells bind to the Fc
region of antibody–antigen complexes on the surface of target
cells and promote target cell lysis. ADCC is primarily mediated
through a set of closely related Fc receptors possessing both
stimulatory and inhibitory activities, with FcgRIIIa being par-
ticularly important. Many published in vitro studies have
reported that infliximab can induce ADCC, although it should
be noted that all of these studies were performed using TNF-
overexpressing cell lines as the target cells [33–35]. Differences in
binding of about 10–20% between FcgRIIIa and CT-P13 or
RMP in NK cells and the resulting ADCC activity were a key
factor in the decision of Health Canada not to approve CT-
P13 in CD and UC [8,12]. However, binding of CT-P13 and
RMP to NK cells was also performed in the presence of diluted
CD patient serum, to mimic the in vivo environment. When
serum was added, the difference between CT-P13 and RMP
was abrogated [8]. Moreover, when lipopolysaccharide (LPS)-
stimulated human monocytes were used as the target cells and
peripheral blood mononuclear cells as the effector cells, no
observable ADCC was seen in response to infliximab [8,36].
Since LPS-stimulated human monocytes are considered repre-
sentative of the target cells encountered in vivo, these results
suggest that ADCC is not likely to play a significant role in
mediating the therapeutic effects of infliximab. Furthermore,
certolizumab, which does not show any ADCC activity in vitro
due to a lack of a Fc region in the protein structure, is effective
and licensed in the USA for reducing the signs and symptoms
of CD, as well as for the treatment of RA, AS, PsA and PsO,
suggesting that ADCC is not a key MOA in these diseases [35].
Pharmacokinetics & biodistribution of RMP & CT-P13
in IBD & non-IBD indications
In clinical studies of the infliximab RMP, no major differences
in pharmacokinetic (PK) parameters were observed in patient
subgroups defined by age, weight or gender. The RMP has a
linear PK profile and overall PK properties of the RMP across
all approved indications are comparable [37].
The equivalence of PK between CT-P13 and RMP was
established in a Phase I study in patients with AS (PLANE-
TAS) (FIGURE 2) [10]. The endpoints of the study were the steady-
state area under the serum–concentration curve (AUC) and
maximum serum concentration (Cmax). PK equivalence was
shown when the 90% confidence intervals (CIs) for the ratios
of both AUC and Cmax (CT-P13/RMP) fell within a prede-
fined margin of 80–125% (AUC: 104.5% [90% CI: 94–
116%]; Cmax: 101.5% [90% CI: 95–109%]). Very close simi-
larity between the PK of CT-P13 and RMP has also been
shown in patients with RA and healthy volunteers [11,38,39].
Tissue biodistribution has not been fully elucidated for
infliximab RMP. It is not known whether there are differences
in clearance or volume of distribution in patients with marked
impairment of hepatic or renal function, and biodistribution is
Review Reinisch, Louis & Danese



























mainly confined to the central vascular
compartment [37,40]. Accelerated clearance
of infliximab has been observed in
patients with acute UC [41] and the pres-
ence of infliximab in the stools of
patients with severe IBD has been
reported [42]. This effect is hypothetically
attributed to IgG loss by capillary leak,
epithelial barrier disruption and immune
cells (exudate) in the feces, which is part
of a complex of protein-losing enteropa-
thy. Due to their comparable structural
and functional properties, this passive dif-
fusion and shedding of RMP IgG and
CT-P13 IgG through the leaky gut wall
is expected to be similar.
The clearance of infliximab can be
influenced by the presence of antidrug
antibodies (ADAs), and concomitant use
of immunomodulators [43]. Prior studies
have established the benefits of the inflix-
imab RMP in the treatment of different
autoimmune diseases, with or without
immunosuppression. Concomitant immunomodulatory thera-
pies have been shown to reduce clearance of infliximab by
suppressing ADA formation [44], but immunomodulators,
including methotrexate (MTX), can also influence infliximab
clearance by ADA-independent mechanisms [43]. Likewise, thio-
purines, and particularly azathioprine, were shown to suppress
ADA formation in CD and UC patients. In UC, the use of
azathioprine and immunomodulatory therapies did not impact
population PK of infliximab [45]. However, azathioprine
showed a trend for reduced ADA rate from 19 to 3% in the
UC patients in the SUCCESS trial [46]. In CD patients, addi-
tion of azathioprine appeared to reduce ADA incidence in the
SONIC study [47] and in prospectively followed cohorts [48],
and also reduce the clearance of infliximab [49]. Moreover, in
CD patients, MTX use with infliximab tended to be associated
with higher median infliximab levels and reduction in ADA
rate in the COMMIT trial [50].
In clinical studies of CT-P13, the PK of this biosimilar was
shown to be comparable with that of the RMP whether
patients received background MTX (as in the Phase III PLAN-
ETRA study in RA) or not (as in the PLANETAS study and a
single-dose study in healthy volunteers) [10,11,38]. Furthermore,
the impact of steroids alone on the PK results in PLANETAS,
and of steroids plus MTX on PK results in PLANETRA, was
evaluated via subgroup analyses. These analyses showed that
regardless of background immunosuppression, the PK of CT-
P13 and RMP were similar across all patient populations [8].
Therefore, it is anticipated that, due to the similarity of PK
and immunogenicity exhibited by CT-P13 and RMP, out-
comes following use of these two drugs will be comparable,
regardless of whether they are administered as monotherapy or
in combination with other immunomodulatory agents.
Biosimilarity has thus been demonstrated between CT-P13
and the RMP with respect to PK in three distinct populations,
namely AS patients, RA patients and healthy volunteers. There-
fore, based on the biosimilarity exercise, it seems scientifically
justified to extrapolate PK profiles for CT-P13 across target
populations and conditions of use.
Clinical experience with CT-P13 in IBD
CT-P13 is now available for clinical use in UC and CD in
many countries; therefore, real-life efficacy and safety data in
these indications can provide essential insights, although it
should be noted that these observations are small and uncon-
trolled and that these data are neither requested nor essential
for the demonstration of biosimilarity (TABLE 1).
CT-P13 has been available for use in patients with IBD in
Korea since July 2012, and data are accumulating in the litera-
ture. Treatment of a small number of patients (n = 17) with CD
or UC in a single center has shown a clinical response to CT-P13
therapy in both indications with no serious or unexpected adverse
events (AEs) reported [51]. Recent data from a Korean post-
marketing study are summarized in full within this supple-
ment [52]. While this study was not powered for evaluating effi-
cacy, positive outcomes were observed in terms of clinical
response. Additionally, to date, no unexpected treatment-related
AEs have been observed in this study. A multicenter retrospective
analysis of 59 patients with CD (32 and 27 TNF antagonist-
naı¨ve or switched from infliximab RMP, respectively) and
51 patients with UC (42 and 9, respectively) was performed in
Korea. In naı¨ve patients with CD, rates of clinical response and
remission at week 30 were 95.5 and 77.3%, respectively; in such
patients with UC, these rates were 91.3 and 47.8%, respectively,
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Figure 2. Mean (SD) serum concentrations of CT-P13 & infliximab RMP over time
in patients with ankylosing spondylitis [10]. Patients were treated with 5 mg/kg
CT-P13 or RMP at weeks 0, 2, 6, and then every 8 weeks up to week 30 (doses 1–6).
Samples for pharmacokinetic analysis were obtained 15 min before infusion, at the end
of the infusion, and at 1 hour post-infusion.
RMP: Reference medicinal product; SD: Standard deviation.




























patients who switched from RMP, a clinical response was main-
tained in 92.6% and 66.7% of CD and UC patients, respec-
tively. AEs related to CT-P13 occurred in 11.8% of UC
patients [53].
In Hungary, interim data from a prospective, nationwide,
observational cohort study of the safety and efficacy of CT-P13
in CD and UC have demonstrated significant decreases from
baseline in disease activity, as assessed by mean Crohn’s Disease
Activity Index (CDAI) and partial Mayo Clinic scores [54].
Another study has shown evidence of mucosal healing in
patients with acute UC after treatment with CT-P13 [55]. Three
recent reports from Poland have focused on experiences with
CT-P13 in a small number of children with IBD. Significant
decreases in Pediatric CDAI score and inflammatory markers
were observed in 10 children with CD after CT-P13 adminis-
tration [56], and in another study, four children with UC expe-
rienced a reduction in Pediatric UC Activity Index scores [57].
No change in disease activity was observed in children with
CD who were switched from infliximab RMP to CT-P13 [58].
In Ireland, a higher rate of surgery in CT-P13-treated
patients compared with RMP-treated patients was reported
(4/14 and 0/22 for CT-P13 and RMP, respectively) [59]. Before
treatment with CT-P13, two patients who had surgery had
higher CRP levels than any RMP-treated patients. In two cases,
surgery was performed within 2 weeks and the remainder
within 6 weeks of initiating CT-P13. Although this is the first
case of comparative data between CT-P13 and RMP in
patients with IBD, there are limitations to the study with
regard to differences in patient disposition and baseline charac-
teristics before treatment and efficacy assessments used.
As an overall summary, CT-P13 has been shown to be effec-
tive in approximately 518 patients with IBD; differences
between CT-P13 and RMP have been reported from the com-
parison of 14 patients treated with CT-P13 and 22 patients
treated with RMP in Ireland. Taken together, data from studies
that have evaluated the use of CT-P13 in patients with IBD
suggest that this biosimilar is effective and generally well toler-
ated. However, further data are welcome, and additional studies
Table 1. Summary of clinical experience with CT-P13 in IBD.
Country Patient numbers Efficacy Safety Ref.
South Korea 173
(CD = 95, UC = 78)
Response: 79.5 and 72.2% in CD and UC
at week 30
Remission: 59.0 and 37.0% in CD and UC
at week 30




(CD = 59, UC = 51)
Naı¨ve: response 95.5 and 91.3% in CD
and UC at week 30; remission 77.3 and
47.8% in CD and UC at week 30
Switch: the efficacy of CT-P13 was
maintained in 92.6 and 66.7% of CD and
UC patients, respectively
AEs related to CT-P13




(CD = 8, UC = 9)
Response: Mayo/CDAI: ~87.5% at





(CD = 57, UC = 33)
Significant decrease in CDAI and partial
Mayo score
Four allergic reactions [54]
Hungary 12
(UC)




(CD = 46, UC = 32)







Switch: pediatric CDAI: 48 (start of RMP)
!8.5 (at switch to CT-P13)
!7.5 (CT-P13 at week 8)




!5 after induction dose





Pediatric UCAI: 47.5 at initiation





Clinical efficacy results were not reported
Surgery: 4 and 0 in CT-P13 and RMP-treated patients, respectively
(in two cases, surgery was performed within 2 weeks and the remainder
within 6 weeks of initiating CT-P13)
[59]
AE: adverse event; CD: Crohn’s Disease; CDAI: Crohn’s disease activity index; UC: Ulcerative colitis; UCAI: Ulcerative colitis activity index.
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that will support the validity of indication extrapolation to
IBD are ongoing. A randomized parallel-group Phase III study
is underway that will assess the noninferiority in efficacy of
CT-P13 compared with infliximab RMP, as well as treatment
safety, in adults with CD [60]. Data for the primary endpoint
of this study (CDAI 70 response at week 54 of treatment) are
expected to be available in early 2016. A global registry study
in IBD has also been initiated [61]. The study is recruiting
adults or children aged ‡6 years with active CD and adults
with fistulizing CD or UC. The primary objective of the study
is to monitor the safety of CT-P13 in IBD patients; efficacy
and health economic parameters will also be assessed.
Conclusions
In the current context, the term ‘extrapolation’ refers to the
process of extending and applying data from clinical studies
obtained in one medical condition or indication to another
medical condition or indication. If biosimilarity to an RMP
has been shown in a comprehensive comparability analysis –
including safety, efficacy and immunogenicity in a key indica-
tion that is suitable to detect potentially relevant differences –
then based on current guidelines, extrapolation may be permis-
sible. Indeed, and although scientific questions have been raised
regarding the validity of this approach with respect to biosimi-
lars, regulatory agencies have provided detailed guidance on the
scientific principles that must be followed in order for extrapo-
lation to be valid. This includes extensive assessments of quality
and biologic activity with results falling within the range
observed for the RMP. In addition, comparable clinical efficacy
and safety must be shown in a sensitive patient population.
Only once this has been established will approval and extrapo-
lation be considered. In the case of CT-P13, evidence from
preclinical MOA studies and clinical PK studies appears to sup-
port the use of this biosimilar in IBD. Evidence emerging from
studies involving ‘real-life’ use of CT-P13 in patients with CD
and UC is in line with the conclusion that this biosimilar is
effective and well tolerated in these populations. Further data
on the use of CT-P13 in IBD are eagerly awaited, particularly
in situations where available data with the RMP are missing, to
help optimize the use of infliximab in IBD.
Expert commentary
Extrapolation of clinical data to cover a range of approved indi-
cations is not a new concept within the field of biologics. Strin-
gent guidelines are in place to show comparability between a
biologic and a biosimilar both in vitro and in the clinic. How-
ever, discussion of the validity of this approach to regulatory
licensing persists. In this article, we have used the approval of
CT-P13 for all indications held by RMP infliximab, as a case
study to highlight how a thorough understanding of the MOAs
of the drug and interpretation of data accumulated during the
development process can be used to support extrapolation.
Emerging results from the clinic for CT-P13 in IBD are
encouraging, and additional studies are planned. The scientific
basis of the extrapolation process is valid for biosimilars but
should be applied on a case-by-case basis after careful scrutiny
of all available data.
Five-year view
A patent cliff for biologics is looming and so the development
and approval of biosimilars is set to rise over the next few
years. As the market grows and healthcare professionals become
more acquainted with biosimilars, the idea and validity of
extrapolation will become more mainstream and questions
relating to this approach to regulatory approval of indications
should be answered. However, strict guidelines and postap-
proval pharmacovigilance must be maintained to ensure patient
safety. The further development of biosimilars will enhance the
treatment options available to patients and the extrapolation of
data will allow the benefits of these new agents to reach as
many patients as possible.
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Key issues
. The EMA approved CT-P13 for all indications held by the infliximab RMP based on evidence from a comprehensive comparability
program that demonstrated equivalence in efficacy, safety and pharmacokinetics.
. The extrapolation of clinical data is fundamental to the development of biosimilars, but its use in the approval process is still subject to
some debate.
. The overexpression of TNF is a common feature of many immune-mediated inflammatory diseases, and the efficacy of TNF antagonists
is well established.
. The role of TNF in the pathogenesis of inflammatory bowel disease (IBD) is varied, but infliximab has been shown to affect key
mechanisms of action including reverse signaling and regulatory macrophage induction. The similarity in this regard between CT-P13
and infliximab reference medicinal product suggests that CT-P13 has comparable effects with infliximab RMP in patients with IBD.
. Emerging real-life efficacy and safety data from patients with IBD treated with CT-P13 support the extrapolation of data to include IBD
indications for CT-P13.
. The extrapolation of clinical data as part of the biosimilar approval process is valid, but requires stringent analysis on a case-by-case
basis. Strict postapproval pharmacovigilance is necessary.
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